Patent Document ID: 20020052410
Application ID: 09805249
Patent Flag: 0

Claim One:
1. A method of treating a neurological activity in an animal, comprising: administering to said animal an effective amount of a compound having an affinity for FKBP-type immunophilins according to formula I 92 or a pharmaceutically acceptable salt thereof, wherein Y is CH 2, O, NH, or N—(C1-C4 alkyl); wherein Z and R 2 are independently Ar, (C5-C7)-cycloalkyl substituted (C1-6)-straight or branched alkyl or alkenyl, (C5-C7)-cycloalkenyl substituted (C1-C6)-straight or branched alkyl or alkenyl, or Ar substituted (C1-C6)-straight or branched alkyl or alkenyl, wherein in each case, one or two carbon atoms of the straight or branched alkyl or alkenyl groups may be substituted with 1-2 heteroatoms selected from the group consisting of oxygen, sulfur, SO and SO 2 in chemically reasonable substitution patterns, or 93 wherein Q is hydrogen, C1-C6)-straight or branched alkyl or (C1-6)-straight or branched alkenyl; wherein T is Ar or substituted 5-7 membered cycloalkyl with substituents at positions 3 and 4 which are independently selected from the group consisting of hydrogen, hydroxyl, O—(C1-C4)-alkyl or O—(C1-C4)-alkenyl and carbonyl; wherein Ar is selected from the group consisting of monocyclic and bicyclic heterocyclic aromatic ring systems with individual ring sizes being 5 or 6 which may contain in either or both rings a total of 1-4 heteroatoms independently selected from oxygen, nitrogen and sulfur; wherein Ar may contain one to three substituents which are independently selected from the group consisting of hydrogen, halo, hydroxyl, hydroxymethyl, nitro, CF 3, trifluoromethoxy, (C1-C6)-straight or branched alkyl or (C1-C6)-straight or branched alkenyl, O—(C1-C4)-straight or branched alkyl or O—(C1-C4)-straight or branched alkenyl, O-benzyl, O-phenyl, amino, 1,2-methylenedioxy, carbonyl and phenyl; wherein R 1 is either hydrogen or U; X is either oxygen or CH—U, provided that if R 1 is hydrogen, then X is CH—U, or if X is oxygen then R 1 is U; wherein U is hydrogen, O—(C1-C4)-straight or branched alkyl or O—(C1-C4)-straight or branched alkenyl, C1-C6)-straight or branched alkyl or (C1-6)-straight or branched alkenyl, (C5-C7)-cycloalkyl, (C5-C7)-cycloalkenyl substituted with (C1-C4)-straight or branched alkyl or C1-C4)-straight or branched alkenyl, &lsqb;C1-C4)-alkyl or (C1-C4)-alkenyl&rsqb;-Ar or Ar (Ar as described above); wherein J is hydrogen or C1 or C2 alkyl or benzyl; K is (C1-C4)-straight or branched alkyl, benzyl or cyclohexylethyl; or wherein J and K may be taken together to form a 5-7 membered heterocyclic ring which may contain an oxygen (O), sulfur (S), SO or SO 2 substituted therein; wherein n is 0-3; and wherein said neurological activity does not include amyotrophic lateral sclerosis.